The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.

Inclusion Criteria (Surveillance Phase) * Between the ages of 18 and 85 years. * Received a single or bilateral lung transplant. * Provided written informed consent prior to transplant Exclusion Criteria (Surveillance Phase) * Is precluded from participating in this study as a result of treatment with another investigational drug or participation in another clinical trial. * If female, the subject is pregnant, lactating or breast feeding. * Any other clinically significant disease or condition, which in the Investigator's medical opinion would preclude the subject's participation in a clinical trial (e.g., recent myocardial infarction). * Is employed or is a first-degree relative of anyone employed by Pulmocide, a participating clinical trial site, or any contract research organisation involved in the study. * Is receiving antiretroviral protease inhibitor therapy. * Has human immunodeficiency virus or chronic, active hepatitis infection, or had a positive hepatitis B surface antigen or hepatitis C virus RNA test prior to transplant. * Any known history or current evidence of alcohol or drug abuse that, in the Investigator's opinion, would exclude the subject from participation in the study Inclusion Criteria (Pre-emptive Treatment Phase) * A positive test for A. fumigatus in BAL during the Surveillance Phase of the study * Provided written informed consent for participating in the Pre-Emptive Treatment Phase. Exclusion Criteria (Pre-emptive Treatment Phase) * Clinical…